ARCA biopharma and Oruka Therapeutics have merged and will now operate under Oruka Therapeutics. The merger agreement includes the combining of all stocks which will now be traded on the Nasdaq under ORKA. The companies anticipate that the merger will fund Oruka’s leading programs, ORKA-001 and ORKA-002, through proof-of-concept. Oruka plans to enter clinical trials for ORKA-001 and ORKA-002 in 2025, with initial pharmacokinetic data for ORKA-001 anticipated in the second half of 2025. The merger and financing are expected to provide resources to propel the programs into clinical development with focus and efficiency.
Source link
ARCA biopharma, Oruka Therapeutics enter merger agreement
